MX2024008583A - Tratamiento de glangliosidosis gm2. - Google Patents
Tratamiento de glangliosidosis gm2.Info
- Publication number
- MX2024008583A MX2024008583A MX2024008583A MX2024008583A MX2024008583A MX 2024008583 A MX2024008583 A MX 2024008583A MX 2024008583 A MX2024008583 A MX 2024008583A MX 2024008583 A MX2024008583 A MX 2024008583A MX 2024008583 A MX2024008583 A MX 2024008583A
- Authority
- MX
- Mexico
- Prior art keywords
- gangliosidosis
- compound
- formula
- specifically
- treatment
- Prior art date
Links
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 title abstract 5
- 208000001905 GM2 Gangliosidoses Diseases 0.000 title abstract 3
- 201000008905 GM2 gangliosidosis Diseases 0.000 title abstract 3
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000021811 Sandhoff disease Diseases 0.000 abstract 2
- 208000022292 Tay-Sachs disease Diseases 0.000 abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22150783.3A EP4209215A1 (en) | 2022-01-10 | 2022-01-10 | Treatment of gm2 gangliosidosis |
| EP22193136 | 2022-08-31 | ||
| PCT/EP2023/050459 WO2023131720A1 (en) | 2022-01-10 | 2023-01-10 | Treatment of gm2 gangliosidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008583A true MX2024008583A (es) | 2024-07-23 |
Family
ID=84982296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008583A MX2024008583A (es) | 2022-01-10 | 2023-01-10 | Tratamiento de glangliosidosis gm2. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250120958A1 (https=) |
| EP (2) | EP4714497A2 (https=) |
| JP (1) | JP2025501646A (https=) |
| AU (1) | AU2023205441A1 (https=) |
| CA (1) | CA3242701A1 (https=) |
| IL (1) | IL314212A (https=) |
| MX (1) | MX2024008583A (https=) |
| TW (1) | TW202337456A (https=) |
| WO (1) | WO2023131720A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202539666A (zh) * | 2024-02-01 | 2025-10-16 | 荷蘭商雅捷法羅斯公司 | Gm1神經節苷脂儲積症之治療 |
| EP4595964A1 (en) * | 2024-02-01 | 2025-08-06 | Azafaros B.V. | Treatment of gm1 gangliosidosis |
| WO2026013261A1 (en) | 2024-07-11 | 2026-01-15 | Azafaros B.V. | Nizubaglustat for use in the treatment of lysosomal storage disorders |
| EP4678174A1 (en) | 2024-07-11 | 2026-01-14 | Azafaros B.V. | Nizubaglustat for use in the treatment of lysosomal storage disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3461812B1 (en) | 2014-03-27 | 2021-10-13 | Academisch Medisch Centrum | N-(5-(biphen-4-ylmethyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
| EP3978474A1 (en) * | 2020-10-02 | 2022-04-06 | Azafaros B.V. | Crystalline forms of a pharmaceutical compound |
-
2023
- 2023-01-10 EP EP25220465.6A patent/EP4714497A2/en active Pending
- 2023-01-10 MX MX2024008583A patent/MX2024008583A/es unknown
- 2023-01-10 JP JP2024539849A patent/JP2025501646A/ja active Pending
- 2023-01-10 EP EP23700690.3A patent/EP4463157B1/en active Active
- 2023-01-10 IL IL314212A patent/IL314212A/en unknown
- 2023-01-10 US US18/727,631 patent/US20250120958A1/en active Pending
- 2023-01-10 CA CA3242701A patent/CA3242701A1/en active Pending
- 2023-01-10 AU AU2023205441A patent/AU2023205441A1/en active Pending
- 2023-01-10 TW TW112101050A patent/TW202337456A/zh unknown
- 2023-01-10 WO PCT/EP2023/050459 patent/WO2023131720A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023131720A1 (en) | 2023-07-13 |
| TW202337456A (zh) | 2023-10-01 |
| EP4714497A2 (en) | 2026-03-25 |
| US20250120958A1 (en) | 2025-04-17 |
| JP2025501646A (ja) | 2025-01-22 |
| EP4463157A1 (en) | 2024-11-20 |
| IL314212A (en) | 2024-09-01 |
| CA3242701A1 (en) | 2023-07-13 |
| EP4463157C0 (en) | 2026-02-25 |
| EP4463157B1 (en) | 2026-02-25 |
| AU2023205441A1 (en) | 2024-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024008583A (es) | Tratamiento de glangliosidosis gm2. | |
| MX389965B (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos | |
| UA92355C2 (en) | urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS | |
| MX2025008327A (es) | Composiciones y metodos para el tratamiento de trastornos del snc | |
| NI200700064A (es) | Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos. | |
| BR0310106A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| SE0403006D0 (sv) | New compounds | |
| EA201170670A1 (ru) | Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета | |
| MX2024013838A (es) | Compuestos y usos de estos | |
| BRPI0412999A (pt) | 2-aminotetralina substituìda para tratamento de depressão | |
| WO2008013987A3 (en) | N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones | |
| MX2021009521A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| BRPI0610644B8 (pt) | composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável. | |
| MX2019013562A (es) | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. | |
| WO2023107723A3 (en) | Cyclic compounds and their use for the treatment of neurological disorders | |
| SA521422728B1 (ar) | مثبطات فوسفوينوسيتيد 3- كيناز الموضعية | |
| JOP20250051A1 (ar) | مُعدِّلات مضاد تربسين ألفا-1 | |
| WO2024023262A3 (en) | Nucleic acid compounds | |
| MX2025001439A (es) | Dímeros de 3-etilamino-indol como agentes serotoninérgicos útiles para el tratamiento de trastornos relacionados con los mismos | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2024006684A (es) | Inhibidores de hdac novedosos y uso terapéutico de estos. | |
| PH12023550007A1 (en) | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome | |
| MX2010003071A (es) | Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor. |